Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (14,240)	$ (36,687)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	32	6
Amortization of right-of-use assets	196	149
Amortization of debt issuance costs	0	1,884
Stock-based compensation	31	5,117
Change in fair value of convertible notes	0	7,469
Change in fair value of Series C convertible preferred stock	0	3,592
Change in fair value of warrant liability	(39)	3,519
Earnings from equity method investment	(9)	(67)
Distribution from equity investment	0	12
Changes in operating assets and liabilities:
Grants receivable	806	0
Prepaid expenses and other current assets	(1,515)	2,667
Other assets	28	(38)
Accounts payable	(1,323)	1,112
Accrued expenses	2,023	(769)
Lease liabilities	(215)	(146)
Deferred revenue	(1,648)	(371)
Other liabilities, noncurrent	220	0
Net cash used in operating activities	(15,653)	(12,551)
Cash flows from investing activities:
Purchases of fixed assets	0	(41)
Net cash used in investing activities	0	(41)
Cash flows from financing activities:
Net proceeds from issuance of common stock upon initial public offering and Concurrent Private Placement, net of discount and commissions	0	110,560
Payment of deferred offering costs	0	(1,665)
Taxes paid related to net share settlement upon vesting of restricted stock awards	0	(1,145)
Proceeds from RSU settlement	0	13
Payment of financing obligation	(14)	0
Exercise of warrants	0	680
Exercise of stock options	0	1
Net cash provided by (used in) financing activities	(14)	108,444
Effect of foreign currency on cash	(87)	(3)
Net increase (decrease) in cash and cash equivalents	(15,754)	95,849
Cash and cash equivalents at the beginning of the period	88,756	34,607
Cash and cash equivalents at the end of the period	73,002	130,456
Supplemental disclosure of noncash investing and financing activities:
Right-of-use assets obtained in exchange for operating lease liabilities	0	618
Deferred offering costs in accrued expenses or accounts payable	0	1,408
Fixed assets purchased in accrued expenses or accounts payable	0	55
IPO
Supplemental disclosure of noncash investing and financing activities:
Conversion of convertible notes into stock	0	58,179
Conversion of Series C preferred stock into common stock upon initial public offering	0	35,754
Net exercise of warrants upon initial public offering	0	13,509
Non-IPO Related Stock Transactions
Supplemental disclosure of noncash investing and financing activities:
Conversion of convertible notes into stock	$ 0	$ 460